# Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

> **NCT05178511** · PHASE2 · UNKNOWN · sponsor: **Li Zhang, MD** · enrollment: 40 (estimated)

## Conditions studied

- The Diagnosis Was ALK Positive NSCLC
- Second Generation ALK-TKI is Resistant
- Efficacy of Ensatinib in This Subset of Patients

## Interventions

- **DRUG:** Ensartinib

## Key facts

- **NCT ID:** NCT05178511
- **Lead sponsor:** Li Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178511, "Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05178511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*